Myeloproliferative Disorders Treatment Market Outlook:
Myeloproliferative Disorders Treatment Market size was valued at USD 6.9 billion in 2024 and is estimated to reach USD 15.5 billion by the end of 2037, exhibiting a CAGR of 7.6% during the forecast period, i.e., 2025-2037. In 2025, the industry size of myeloproliferative disorders treatment is assessed at USD 7.5 billion.
According to the report of the National Institute of Health, myeloproliferative disorder is diagnosed among approximately 350,000 patients annually worldwide. Polycythemia and myelofibrosis are the most common traits within the diagnosed patient as per medical evaluation. The aging population is vulnerable to health risks due to myeloproliferative disorders. Demographic switch and growth in the aged population are expected to leverage the demand for myeloproliferative disorders treatment in the global market. Government support in the elevation of myeloproliferative disorders treatment is considerably high, which ensured better infrastructure and R&D for better patient outcomes. The inclusion of personalized medicine advancements like AI-driven drug directed to reduce the trial time and enhance the treatment procedure throughout the world.
Furthermore, active pharmaceutical ingredients (APIs) are the primary raw material that is required for myeloproliferative disorders therapy. Europe and North America are the dominant markets in the production of JAK inhibitor API, whereas hydroxyurea is predominantly supplied from India and China. According to the data published by the U.S. Bureau of Labor Statistics, the producer price index for MPD drugs rose by 4.3% and the consumer price index for treatments increased by 7.2%. The high market demand resulted a rise in API price and cost of the therapy in the global market. According to the reporting of the National Health Institute, approximately USD 2.9 billion is invested in research, development, and deployment in the myeloproliferative disorders, and 76% of clinical trials are for JAK inhibitors and gene therapy.
